Imipenem + Cilastatina Aurovitas

Imipenem, the active ingredient in Imipenem + Cilastatina Aurovitas, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It provides broad‑spectrum activity against Gram‑positive and Gram‑negative bacteria and is employed to treat serious infections such as complicated intra‑abdominal infections, urinary tract infections, hospital‑acquired pneumonia, meningitis, and septicemia in hospitalized patients.

GNH USA supplies Imipenem + Cilastatina Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics and specialized care facilities worldwide.

Imipenem/cilastatin is a carbapenem antibiotic used to treat severe bacterial infections across several organ systems.

Complicated intra‑abdominal infection: rapid bacterial eradication leading to clinical improvement. Complicated urinary tract infection: eradication of uropathogens and resolution of infection. Hospital‑acquired pneumonia: effective against resistant pathogens causing lower respiratory infection. Meningitis: penetrates the cerebrospinal fluid to treat central nervous system infections. Septicemia: broad‑spectrum coverage for bloodstream infections caused by susceptible organisms.

Adverse reactions may occur with imipenem/cilastatin therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhea: may be watery and self‑limiting. - Rash: skin erythema or pruritus. - Headache: transient cephalic pain. - Elevated liver enzymes: mild transaminase increase. - Injection site pain: local discomfort during infusion.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or high doses. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile colitis: antibiotic‑associated severe diarrhea. - Neutropenia: marked reduction in neutrophil count. - Renal failure: worsening kidney function in susceptible individuals.

Use imipenem/cilastatin with caution in specific clinical situations.

Renal function: adjust dosing in patients with impaired renal clearance. Allergy: avoid in individuals with known hypersensitivity to β‑lactam antibiotics or cilastatin. Seizure risk: monitor patients with central nervous system disorders or receiving high doses. Drug interactions: review concomitant medications that may lower seizure threshold. Pregnancy: consider only if potential benefits outweigh risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imipenem/cilastatin may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Valproic acid: may reduce serum valproate levels, increasing seizure risk. - CNS depressants: concurrent use can lower seizure threshold. - Renal dehydropeptidase inhibitors: may interfere with cilastatin activity.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity potential. - Loop diuretics: may increase risk of ototoxicity. - Anticoagulants: possible enhancement of anticoagulant effect, requiring INR monitoring.